AMC Community Endocrinology

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes11 trials
• Obesity4 trials
• Type 1 diabetes2 trials

Phase

• Phase 312 trials
• Phase 22 trials

Status

• Completed10 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials

Lead sponsor

• Novo Nordisk A/S13 trials
• vTv Therapeutics1 trial

Running trials

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  NCT07931599· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

  NCT06334133· Phase 3· vTv Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting

Closed trials

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06542874· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

  NCT06269107· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

  NCT05649137· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

  NCT05486065· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source